Constraints on Dark Energy from New Observations including Pan-STARRS

In this paper, we set the new limits on the equation of state parameter (EoS) of dark energy with the observations of cosmic microwave background radiation (CMB) from Planck satellite, the type Ia supernovae from Pan-STARRS and the baryon acoustic oscillation (BAO). We consider two parametrization forms of EoS: a constant $w$ and time evolving $w(a)=w_0+w_a(1-a)$. The results show that with a constant EoS, $w=-1.141\pm{0.075}$ ($68\%~C.L.$), which is consistent with $\Lambda$CDM at about $2\sigma$ confidence level. For a time evolving $w(a)$ model, we get $w_0=-1.09^{+0.16}_{-0.18}$ ($1\sigma~C.L.$), $w_a=-0.34^{+0.87}_{-0.51}$ ($1\sigma~C.L.$), and in this case $\Lambda$CDM can be comparable with our observational data at $1\sigma$ confidence level. In order to do the parametrization independent analysis, additionally we adopt the so called principal component analysis (PCA) method, in which we divide redshift range into several bins and assume $w$ as a constant in each redshift bin (bin-w). In such bin-w scenario, we find that for most of the bins cosmological constant can be comparable with the data, however, there exists few bins which give $w$ deviating from $\Lambda$CDM at more than $2\sigma$ confidence level, which shows a weak hint for the time evolving behavior of dark energy. To further confirm this hint, we need more data with higher precision.Comment: 9 pages, 8 figures, 1 tabl

Validated method to measure yakuchinone A in plasma by LC-MS/MS and its application to a pharmacokinetic study in rats

BACKGROUND: Yakuchinone A has a plethora of beneficial biological effects. However, the pharmacokinetic (PK) data of yakuchinone A still remain unknown so far. Furthermore, the quantification of yakuchinone A in biological samples has not been reported in the literature. Therefore, in the present study we aimed to develop a new method for the fast, efficient and accurate assessment of yakuchinone A concentration in plasma, as a means for facilitating the PK evaluation of yakuchinone A. RESULTS: A liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) method was developed and validated for the determination of yakuchinone A in rat plasma. Mass spectrometric and chromatographic conditions were optimized. Plasma samples were pretreated by protein precipitation with methanol. LC separation was performed on a Phenomenex Luna C18 column with gradient elution using a mobile phase consisting of methanol–water containing 0.5 mM formic acid (HCOOH) at a flow rate of 0.28 mL/min. ESI-MS spectra were acquired in positive ion multiple reaction monitoring mode (MRM). The precursor-to-product ion pairs used for MRM of yakuchinone A and yakuchinone B were m/z 313.1 → 137.0 and 311.2 → 117.1, respectively. Low concentration of HCOOH reduced the ion suppression caused by matrix components and clearly improved the analytical sensitivity. Yakuchinone A showed good linearity over a wide concentration range (r > 0.99). The accuracy, precision, stability and linearity were found to be within the acceptable criteria. This new method was successfully applied to analyze the rat plasma concentration of parent yakuchinone A after a single oral administration of SuoQuan capsules. Low systemic exposure to parent yakuchinone A was observed. CONCLUSION: The proposed method is sensitive and reliable. It is hoped that this new method will prove useful for the future PK studies